![](https://static.scientificamerican.com/sciam/cache/file/AFA5C76B-E908-48D1-B328A1C46BE9A584_agenda.jpg?w=275&h=154&fit=crop)
Eye Drops Recalled after Deaths and Blindness—Here’s What to Know
Here’s how to tell whether your eye drops are safe to use and how to recognize a potential infection
Here’s how to tell whether your eye drops are safe to use and how to recognize a potential infection
A judge’s decision could ban mifepristone across the country and weaken the Food and Drug Administration’s authority
Concerns about Paxlovid rebound are preventing some doctors from prescribing the lifesaving drug and some high-risk patients from taking it
A laboratory study unravels ways antidepressants and other nonantibiotic drugs can contribute to drug resistance
Drugs that reduce excess weight linked to chronic health problems have shown striking results in trials and in practice
Current monoclonal antibodies fail against COVID virus variants, so drugmakers want to use a fast-track test for new ones
A hemophilia drug has the potential to save lives. But it cannot treat the most common form of the disease
Eisai and Biogen share clinical trial data confirming that lecanemab slows mental decline amid reports of potentially related deaths
If the U.S. Food and Drug Administration approves the first over-the-counter birth control pill, pharmacists and pharmacies could play an ever increasing role in reproductive health care...
A scientist who has been developing male birth control since the 1970s says safe, reversible and affordable options are possible
A legal battle over nitrogen hypoxia, a new potential method of execution, raises ethical questions
Compounds that marine creatures make to defend themselves could yield lifesaving medicines
The antiviral Tecovirimat (TPOXX) shows promise against monkeypox, but human data and supplies are limited
A smallpox antiviral that’s effective against monkeypox is tied up in red tape, and gay-health advocates are pushing to make it easier to access
People who are unlikely to develop severe COVID-19 have no widely approved medications to ease the illness
The risks associated with hormonal contraception are lower than the risk of pregnancy itself and comparable to those of other over-the-counter drugs
Drugs such as mifepristone and misoprostol end a pregnancy, whereas the “morning-after pill” works by preventing one
The success of vaccines has reduced the pool of people available for studies, among other factors
A global look reveals contamination by antibiotics, antidepressants and other medications
An individual’s health risks, treatment access and local case levels come into play for those who are eligible
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account